Which Berinert patents matter (and what are they for)?
Berinert is the brand name for human C1 esterase inhibitor (C1-INH), used to treat hereditary angioedema (HAE). The key patents people usually mean are those that protect:
- the specific product formulation and manufacturing process for Berinert
- dosing/regimens for HAE
- methods of treatment claims for HAE patients
Because “Berinert patent” can refer to different jurisdictions and different claim types, the most practical way to identify the relevant patents is by searching by the exact product name and active ingredient (C1 esterase inhibitor) in the patent office where you care about protection (e.g., USPTO for the U.S., EP register for Europe).
When does Berinert’s exclusivity/patent protection expire?
Patent and exclusivity timelines depend on the country and on which specific patent family (and which type of protection) you mean. For branded biologics like Berinert, the effective “no-competition” clock often reflects more than one protection layer, such as:
- one or more composition/formulation patents
- process/manufacturing patents
- method-of-use patents
- regulatory exclusivities (which can extend beyond the first patent expiry)
To get an accurate “expiry date,” you need the specific patent numbers or at least the jurisdiction and applicant/assignee, then check each listed expiry in that country’s registry.
Are there court cases or challenges to Berinert patents?
If a biosimilar or follow-on company wants to launch a competing C1-INH product, it can challenge the brand’s protected claims (or argue non-infringement/invalidity). These disputes often show up as:
- patent infringement lawsuits
- settlement agreements (sometimes with launch-date commitments)
- procedural events around claim scope
If you share the country (U.S., EU, etc.) and any company name you have in mind, I can help map the likely litigation landscape and the patents typically asserted.
Who makes Berinert, and how does that affect which patents are listed?
Patent ownership and assignment matter. The same product name can have patents listed under different assignees due to acquisitions or licensing. Identifying the current brand authorization holder (and the original assignee) helps narrow which patent families you should check.
What’s the fastest way to find the exact Berinert patent numbers?
Use a patent database search with these constraints:
- Product: “Berinert”
- Active ingredient: “C1 esterase inhibitor” (or “C1-INH”)
- Jurisdiction: USPTO, EPO, or your target country
- Assignee/applicant: the company that holds Berinert authorization in that region
Then filter results for:
- composition/formulation claims
- process/manufacturing claims
- method-of-use claims referencing HAE
What I need from you to answer precisely
“Berinert patent” is too broad to give a single definitive answer. Tell me:
1) Which country/jurisdiction (U.S., Europe/EP, UK, Canada, etc.)?
2) Do you want the patent on the product itself, the manufacturing process, or the method of treating HAE?
3) If you have it, share any patent number, applicant/assignee, or competitor name (biosimilar/follow-on).
With those details, I can point you to the specific patents and explain how their claims map to Berinert and the likely expiry/exclusivity timeline in that jurisdiction.